Hancock Whitney’s Sanofi SNY Stock Holding History

Hancock Whitney’s Portfolio SNY Stock Details SNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-4,272	Closed	-$214K	–	653
2022 Q2	$214K	Sell	4,272 -172	-4%	-$9.13K	0.01%	605
2022 Q1	$228K	Sell	4,444 -823	-16%	-$42.5K	0.01%	638
2021 Q4	$264K	Buy	5,267 +614	+13%	+$30.4K	0.01%	614
2021 Q3	$224K	Sell	4,653 -663	-12%	-$33.7K	0.01%	634
2021 Q2	$280K	Buy	+5,316	New	+$277K	0.01%	698

Other funds holding SNY

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Hancock Whitney's SNY Position: Q3 2022 in Review

Hancock Whitney sold out of Sanofi (SNY) in Q3 2022, closing a stake of 4,272 shares — an estimated $214K sold.

Hancock Whitney first reported a position in SNY in Q2 2021 and held it in 5 quarters. The position peaked at $280K in Q2 2021. 587 funds tracked by Wall St. Rank hold SNY as of Q3 2022.

Hancock Whitney reported no remaining Sanofi position as of Q3 2022 after selling out during the quarter.
Hancock Whitney sold 4,272 Sanofi shares in Q3 2022, an estimated $214K.
Hancock Whitney first reported a position in Sanofi in Q2 2021 and held it in 5 quarters.
Hancock Whitney's Sanofi position peaked at $280K in Q2 2021.
587 funds tracked by Wall St. Rank held Sanofi as of Q3 2022.

Based on Hancock Whitney's 13F filing for Q3 2022, filed 26 Oct 2022.